The resolution calls for increased awareness, advocacy, and educational efforts related to cholangiocarcinoma. Supporters of the bill believe that raising awareness on this issue is crucial as it could lead to earlier detection and improved patient outcomes. Highlighting the importance of this day serves to unite various organizations, research institutions, and advocates aimed at fighting this cancer and seeking potential advancements in treatment options.
Summary
Senate Resolution 737 (SR0737) is introduced to recognize February 18, 2024, as World Cholangiocarcinoma Day. The resolution highlights cholangiocarcinoma, a rare form of bile duct cancer, emphasizing the increasing number of diagnoses in the United States, with approximately 12,000 individuals affected annually. It notes that the mortality rate for this cancer has been rising significantly over the past decade due to late-stage diagnosis, which is often attributed to the lack of any validated early detection methods.
Contention
While the bill is largely supportive and uncontroversial, it may bring attention to the larger issue regarding funding for research into rare cancers. As cholangiocarcinoma is characterized by a low five-year survival rate of about 20%, discussions could arise about allocating more resources and attention towards healthcare initiatives targeting rare cancers, which are often overshadowed by more common diseases.
Vietnam Veterans Liver Fluke Cancer Study ActThis bill requires the Department of Veterans Affairs (VA) to conduct an epidemiological study and report on the prevalence of cholangiocarcinoma (bile duct cancer) in veterans who served in the Vietnam theater of operations during the Vietnam era. The study must identify the rate of incidence of cholangiocarcinoma in such veterans and in U.S. residents.The bill also requires the VA to track and report on the prevalence of cholangiocarcinoma using the Veterans Affairs Central Cancer Registry. Additionally, the VA must periodically submit follow-up reports to Congress regarding the epidemiological study and information collected from the cancer registry regarding the prevalence of bile duct cancer.